References
Phillips LH: The epidemiology of myasthenia gravis. Semin Neurol 2004, 24:17–20.
Hauser RA, Malek AR, Rosen R: Successful treatment of a patient with severe refractory myasthenia gravis using mycophenolate mofetil. Neurology 1998, 51:912–913.
Ciafaloni E, Massey JM, Tucker-Lipscomb B, Sanders DB: Mycophenolate mofetil for myasthenia gravis: an open-label pilot study. Neurology 2001, 56:97–99.
Chaudhry V, Cornblath DR, Griffin JW, et al.: Mycophenolate mofetil: a safe and promising immunosuppressant in neuromuscular diseases. Neurology 2001, 56:94–96.
Meriggioli MN, Rowin J, Richman JG, Leurgans S: Mycophenolate mofetil for myasthenia gravis: a double-blind, placebo-controlled pilot study. Ann N Y Acad Sci 2003, 998:494–499.
Meriggioli MN, Ciafaloni E, Al-Hayk KA, et al.: Mycophenolate mofetil for myasthenia gravis: an analysis of efficacy, safety, and tolerability. Neurology 2003, 61:1438–1440.
Rights and permissions
About this article
Cite this article
Hirano, M. Two strikes against mycophenolate mofetil therapy for myasthenia gravis. Curr Neurol Neurosci Rep 9, 57–58 (2009). https://doi.org/10.1007/s11910-009-0009-6
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11910-009-0009-6